Vaxxing

Pfizer’s sales soar to a record, driven by vaccines and Covid pills as cases resurge

Snacks / Thursday, July 28, 2022

Shoot your (multi-billion dollar) shot... Pfizer's sales hit a record high last quarter, surging 27% from last year to nearly $28B. More than half of that revenue came from Covid shots or Covid treatments. Meanwhile, total profit ballooned 78% to nearly $10B.

  • Pfizer's Covid vax (still the most popular in the US by far) brought in $8.8B in revenue. Compare that to J&J, which made just $544M from Covid vax sales last quarter.
  • Pfizer's antiviral pill Paxlovid, used to prevent severe sickness in high-risk Covid patients, brought in $8.1B. Merck also reported strong growth yesterday, partly thanks to $1.2B in revenue from its Covid pill Lagevrio. Merck's total profit 3X'd from last year.
  • Still: Pharma stocks tumbled yesterday after Senate Dems reached a deal they say will lower prescription drug costs.

Halloween and vaccines... If it seems like everyone’s getting Covid, that’s because the dominant BA.5 Omicron subvariant is more transmissible than past ones. As Covid resurges, the FDA has asked vaccine-makers to target dominant subvariants for a wave of fall boosters. Last month, Pfizer and its vax partner BioNTech struck a $3.2B deal with the US gov't to deliver 105M doses ahead of an increasingly-likely fall vaccination campaign.

Out of mind ≠ out of sight… The pandemic used to dominate every headline and conversation. It isn’t monopolizing our daily lives like it was two years ago — from loosening restrictions to lessening news coverage. Still, the US is dealing with 130K new daily Covid cases and a rising death toll. For reference: daily cases are at the same high level that they were in November 2020. Now, health officials worry that the US will face an even bigger wave when summer ends — and vax-makers will be key to tackling it.

Get Your News

Subscribe and thrive

Snacks provides fresh takes on the financial news you need to start your day. Chartr provides data visualizations on business, entertainment, and society. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.